文献速递眼底病与葡萄膜炎

吸烟状态与新生血管性年龄相关性黄斑变性抗血管内皮生长因子抑制剂治疗结局的关系

SMOKING STATUS AND TREATMENT OUTCOMES OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
PubMed 文献 · Retina · 2020-01-01

基于Fight Retinal Blindness!多国观察性数据库的回顾性分析,纳入987只未治疗过的新生血管性年龄相关性黄斑变性眼,评估吸烟状态对1年视力结局的影响。完成12个月治疗者中,不吸烟、已戒烟和当前吸烟者平均视力改善分别为7.7、6.1和3.5个字母(P=0.046),当前吸烟者开始治疗时较不吸烟者平均年轻6.2岁(P<0.001)。

要点

  • 完成12个月治疗者中,不吸烟、已戒烟、当前吸烟者平均视力改善分别为7.7、6.1、3.5个字母(P=0.046)。
  • 12个月治疗期间中位注射次数按吸烟状态无显著差异。
  • 当前吸烟者开始治疗时较不吸烟者平均年轻6.2岁(P<0.001)。

核心结论

  • 本研究发现在接受血管内皮生长因子抑制剂治疗新生血管性年龄相关性黄斑变性期间继续吸烟的患者12个月视力结局较差。

研究设计与样本

  • 回顾性分析来自前瞻性设计的多中心观察性数据库的数据。
  • 纳入澳大利亚、新西兰、新加坡和瑞士经Fight Retinal Blindness!结局登记系统追踪的987只未治疗过的新生血管性年龄相关性黄斑变性眼,基线有吸烟状态记录并于2006年1月至2016年12月起始血管内皮生长因子抑制剂治疗。
  • 采用广义相加模型展示视力结果。

主要发现

  • 完成12个月治疗的患者中,调整年龄、基线视力、脉络膜新生血管膜病变类型并按诊所嵌套后,不吸烟者、已戒烟者与当前吸烟者12个月平均视力改善差异显著(7.7 vs. 6.1 vs. 3.5个字母变化;P=0.046)。
  • 12个月治疗期间中位注射次数按吸烟状态无显著差异。
  • 当前吸烟者开始治疗时较不吸烟者平均年轻6.2岁(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess whether smoking status affects 1-year visual outcomes in eyes treated with vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. METHODS: Retrospective analysis of data from a prospectively designed, multicenter, observational database. Nine hundred and eighty seven treatment-naive eyes of patients with neovascular age-related macular degeneration were tracked by the Fight Retinal Blindness! outcome registry in Australia, New Zealand, Singapore, and Switzerland who had documented smoking status at baseline and commenced vascular endothelial growth factor inhibitor therapy from January 2006 to December 2016. Generalized additive models were used to display visual acuity results. RESULTS: There was a significant difference in mean improvement in visual acuity at 12 months between nonsmokers, ex-smokers, and current smokers (7.7 vs. 6.1 vs. 3.5 letters of change; P = 0.046) among patients who completed 12 months of treatment when adjusted for age, baseline visual acuity, and choroidal neovascular membrane lesion type and nested for practice. There was no significant difference in the median number of injections over 12 months of treatment by smoking status. Current smokers were a mean of 6.2 years younger than nonsmokers when they started treatment (P < 0.001). CONCLUSION: This study found inferior 12-month visual outcomes in patients who continued to smoke while receiving vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Vittorio AF, Nguyen V, Barthelmes D, et al. SMOKING STATUS AND TREATMENT OUTCOMES OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2020. PMID: 31613840. doi:10.1097/IAE.0000000000002679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。